Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
In this issue of the Journal, there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against α 4 integrins. 1 – 3 These patients were among 3000 who had participated i...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2005-07, Vol.353 (4), p.414-416 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 4 |
| container_start_page | 414 |
| container_title | The New England journal of medicine |
| container_volume | 353 |
| creator | Berger, Joseph R Koralnik, Igor J |
| description | In this issue of the
Journal,
there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against α
4
integrins.
1
–
3
These patients were among 3000 who had participated in clinical trials of natalizumab for the treatment of multiple sclerosis or Crohn's disease. PML is a deadly opportunistic infection of the central nervous system (CNS) for which there is no specific treatment. It is caused by reactivation of a clinically latent JC polyomavirus infection. This virus infects and destroys oligodendrocytes, leading to multifocal areas of demyelination and . . . |
| doi_str_mv | 10.1056/NEJMe058122 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1056_NEJMe058122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15947082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-1940b1fa64d20a318f8807569ac0f31811b8f6e3bc09ac25dcf67546a4520ce43</originalsourceid><addsrcrecordid>eNptkM1OwzAQhC0EoqVw4o4scUSBtWM7yRFV5U8tcKBcI8dZ05T8ESdI5cRD8IQ8CalaCQ7sZbWrb0ajIeSYwTkDqS7uJ3czBBkyznfIkEnf94QAtUuGADz0RBD5A3Lg3BL6YSLaJwMmIxFAyIfk-bGpXhp0LntHOuvyNrOV0TmdYvdaYWmwXui8qnW7WFFdpvRetzrPPrpCJ_T784vOS1v1csSSjqvS4Vu3FrlDsmd17vBou0dkfjV5Gt9404fr2_Hl1DN9wtZjkYCEWa1EykH7LLRhCIFUkTZg-5OxJLQK_cRA_-IyNVYFUigtJAeDwh-Rs42vaSrnGrRx3WSFblYxg3jdTvynnZ4-2dB1lxSY_rLbOnrgdAMUhYtLXBb_2vwAZVRsJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Berger, Joseph R ; Koralnik, Igor J</creator><creatorcontrib>Berger, Joseph R ; Koralnik, Igor J</creatorcontrib><description>In this issue of the
Journal,
there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against α
4
integrins.
1
–
3
These patients were among 3000 who had participated in clinical trials of natalizumab for the treatment of multiple sclerosis or Crohn's disease. PML is a deadly opportunistic infection of the central nervous system (CNS) for which there is no specific treatment. It is caused by reactivation of a clinically latent JC polyomavirus infection. This virus infects and destroys oligodendrocytes, leading to multifocal areas of demyelination and . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe058122</identifier><identifier>PMID: 15947082</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal, Humanized ; Brain - pathology ; Crohn Disease - drug therapy ; Disease Progression ; Humans ; JC Virus ; Leukoencephalopathy, Progressive Multifocal - chemically induced ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Natalizumab ; Opportunistic Infections - chemically induced</subject><ispartof>The New England journal of medicine, 2005-07, Vol.353 (4), p.414-416</ispartof><rights>Copyright © 2005 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-1940b1fa64d20a318f8807569ac0f31811b8f6e3bc09ac25dcf67546a4520ce43</citedby><cites>FETCH-LOGICAL-c406t-1940b1fa64d20a318f8807569ac0f31811b8f6e3bc09ac25dcf67546a4520ce43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe058122$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMe058122$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26102,27923,27924,52381,54063</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15947082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berger, Joseph R</creatorcontrib><creatorcontrib>Koralnik, Igor J</creatorcontrib><title>Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this issue of the
Journal,
there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against α
4
integrins.
1
–
3
These patients were among 3000 who had participated in clinical trials of natalizumab for the treatment of multiple sclerosis or Crohn's disease. PML is a deadly opportunistic infection of the central nervous system (CNS) for which there is no specific treatment. It is caused by reactivation of a clinically latent JC polyomavirus infection. This virus infects and destroys oligodendrocytes, leading to multifocal areas of demyelination and . . .</description><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Brain - pathology</subject><subject>Crohn Disease - drug therapy</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>JC Virus</subject><subject>Leukoencephalopathy, Progressive Multifocal - chemically induced</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Natalizumab</subject><subject>Opportunistic Infections - chemically induced</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkM1OwzAQhC0EoqVw4o4scUSBtWM7yRFV5U8tcKBcI8dZ05T8ESdI5cRD8IQ8CalaCQ7sZbWrb0ajIeSYwTkDqS7uJ3czBBkyznfIkEnf94QAtUuGADz0RBD5A3Lg3BL6YSLaJwMmIxFAyIfk-bGpXhp0LntHOuvyNrOV0TmdYvdaYWmwXui8qnW7WFFdpvRetzrPPrpCJ_T784vOS1v1csSSjqvS4Vu3FrlDsmd17vBou0dkfjV5Gt9404fr2_Hl1DN9wtZjkYCEWa1EykH7LLRhCIFUkTZg-5OxJLQK_cRA_-IyNVYFUigtJAeDwh-Rs42vaSrnGrRx3WSFblYxg3jdTvynnZ4-2dB1lxSY_rLbOnrgdAMUhYtLXBb_2vwAZVRsJg</recordid><startdate>20050728</startdate><enddate>20050728</enddate><creator>Berger, Joseph R</creator><creator>Koralnik, Igor J</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20050728</creationdate><title>Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences</title><author>Berger, Joseph R ; Koralnik, Igor J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-1940b1fa64d20a318f8807569ac0f31811b8f6e3bc09ac25dcf67546a4520ce43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Brain - pathology</topic><topic>Crohn Disease - drug therapy</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>JC Virus</topic><topic>Leukoencephalopathy, Progressive Multifocal - chemically induced</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Natalizumab</topic><topic>Opportunistic Infections - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berger, Joseph R</creatorcontrib><creatorcontrib>Koralnik, Igor J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berger, Joseph R</au><au>Koralnik, Igor J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2005-07-28</date><risdate>2005</risdate><volume>353</volume><issue>4</issue><spage>414</spage><epage>416</epage><pages>414-416</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In this issue of the
Journal,
there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against α
4
integrins.
1
–
3
These patients were among 3000 who had participated in clinical trials of natalizumab for the treatment of multiple sclerosis or Crohn's disease. PML is a deadly opportunistic infection of the central nervous system (CNS) for which there is no specific treatment. It is caused by reactivation of a clinically latent JC polyomavirus infection. This virus infects and destroys oligodendrocytes, leading to multifocal areas of demyelination and . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>15947082</pmid><doi>10.1056/NEJMe058122</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2005-07, Vol.353 (4), p.414-416 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_crossref_primary_10_1056_NEJMe058122 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Brain - pathology Crohn Disease - drug therapy Disease Progression Humans JC Virus Leukoencephalopathy, Progressive Multifocal - chemically induced Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab Opportunistic Infections - chemically induced |
| title | Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A50%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20Multifocal%20Leukoencephalopathy%20and%20Natalizumab%20%E2%80%94%20Unforeseen%20Consequences&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Berger,%20Joseph%20R&rft.date=2005-07-28&rft.volume=353&rft.issue=4&rft.spage=414&rft.epage=416&rft.pages=414-416&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe058122&rft_dat=%3Cpubmed_cross%3E15947082%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15947082&rfr_iscdi=true |